Over 100 new genomic regions linked to blood pressure were discovered, offering insights into iron metabolism and potential ...

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

National Institutes of Health researchers and collaborators have discovered over 100 new regions of the human genome, also ...

Beta-blockers are effective at decreasing the morbidity and mortality associated with CHF. They lower the risk of all-cause mortality, cardiovascular mortality, sudden death, and death from ...

Treatment of overactive bladder can be more complex in the context of benign prostatic hyperplasia, but a new trial met ...

Very interestingly, we also found that patients with end-stage heart failure have upregulated gene and protein levels of ...

For instance, in the case of SSRI-induced night sweats, some people have seen improvement by adding medications called alpha-adrenergic blockers, research shows. Waking up drenched every once in a ...

a selective alpha-2 adrenergic receptor agonist. BioXcel Therapeutics believes that BXCL501 potentially targets an important mediator of agitation, and the Company has observed anti-agitation results ...

adrenergic receptor blocking agent that slows the sinus rate and decreases AV nodal conduction. The β-blocking activity of metoprolol has been shown by reduction in heart rate and cardiac output ...

In addition, Ocuphire has a partnership with Viatris to develop and commercialize PS, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size. PS was approved by the ...

This came after Eris Lifescience presented the proposal along with the Phase III clinical trial report before the committee.